Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-12-31.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
13.51%
RETURN ON EQUITY (ROE) AVG 3Y
15.58%
RETURN ON EQUITY (ROE) AVG 5Y
15.05%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Jyong Biotech Ltd. Ordinary Shares
Market Cap
$155.86M
Return on Equity (ROE)
N/A
TTM Avg
13.51%
3Y Avg
15.58%
5Y Avg
15.05%
Market Cap
$157.57M
Return on Equity (ROE)
-14.07%
TTM Avg
-16.23%
3Y Avg
-27.66%
5Y Avg
-19.01%
Market Cap
$153.40M
Return on Equity (ROE)
-59.40%
TTM Avg
-255.06%
3Y Avg
-160.44%
5Y Avg
-112.56%
Market Cap
$159.09M
Return on Equity (ROE)
N/A
TTM Avg
101.44%
3Y Avg
117.16%
5Y Avg
-25.56%
Market Cap
$151.66M
Return on Equity (ROE)
-93.22%
TTM Avg
-92.28%
3Y Avg
-73.94%
5Y Avg
-53.80%
Market Cap
$151.58M
Return on Equity (ROE)
-155.34%
TTM Avg
-168.75%
3Y Avg
-117.97%
5Y Avg
-104.46%
Market Cap
$149.34M
Return on Equity (ROE)
-21.38%
TTM Avg
-42.33%
3Y Avg
-37.95%
5Y Avg
-45.57%
Market Cap
$149.15M
Return on Equity (ROE)
-183.44%
TTM Avg
-114.28%
3Y Avg
-67.72%
5Y Avg
-46.03%
Market Cap
$162.89M
Return on Equity (ROE)
-60.19%
TTM Avg
-68.34%
3Y Avg
-61.91%
5Y Avg
-47.91%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jyong Biotech Ltd. Ordinary Shares (MENS) | $155.86M | N/A | 13.51% | 15.58% | 15.05% |
| Inogen, Inc. (INGN)vs › | $157.57M | -14.07% | -16.23% | -27.66% | -19.01% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $153.40M | -59.40% | -255.06% | -160.44% | -112.56% |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.09M | N/A | 101.44% | 117.16% | -25.56% |
| Codexis, Inc. (CDXS)vs › | $151.66M | -93.22% | -92.28% | -73.94% | -53.80% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | -155.34% | -168.75% | -117.97% | -104.46% |
| Anavex Life Sciences Corp. (AVXL)vs › | $149.34M | -21.38% | -42.33% | -37.95% | -45.57% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $149.15M | -183.44% | -114.28% | -67.72% | -46.03% |
| PepGen Inc. (PEPG)vs › | $162.89M | -60.19% | -68.34% | -61.91% | -47.91% |
| Coherus Oncology, Inc. (CHRS)vs › | $163.00M | -215.26% | -150.35% | 8.65% | -35.35% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 18.75% |
| 2024-12-31 | 8.27% |
| 2023-12-31 | 12.91% |
| 2022-12-31 | 22.38% |
| 2021-12-31 | 18.00% |
| 2020-12-31 | 9.98% |
